Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Study Reclassifies HPV-Positive Head and Neck Cancer

May 26th 2017

Iain Morgan, PhD, discusses research that redefines HPV-positive head and neck cancer and may also identify new therapeutic targets.

The Development of Galectin-1 for Head and Neck Cancer

May 24th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the importance of continuing to study Galectin-1 for patients with head and neck cancer.

Future of Immunotherapy in Head and Neck Cancer May Be in Combinations

May 22nd 2017

Researchers are hoping to build on the success of the KEYNOTE-012 and CheckMate-141 trials, which led to the approvals of pembrolizumab and nivolumab, respectively, by examining anti–PD-1/PD-L1 agents in the frontline and as a part of combination regimens for patients with head and neck cancer.

Study Spotlights Patient Difficulties When Opting Against Thyroid Cancer Treatment

May 19th 2017

Louise Davies, MD, discusses the experience of patients with incidentally identified thyroid cancer who choose to not receive treatment.

Dr. Papa on Leukapheresis Manufacturing Approach in Head and Neck Cancer

May 18th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses leukapheresis manufacturing approach in head and neck cancer.

Experts Respond to USPSTF Recommendation Against Thyroid Cancer Screening

May 11th 2017

The US Preventive Services Task Force announced that it recommends against screening for thyroid cancer in asymptomatic adults.

PD-L1 Expression Strongly Associated With Radiation Resistance in HPV-Negative HNSCC

May 11th 2017

High PD-L1 expression is closely associated with local failure following radiotherapy in HPV-negative head and neck squamous cell carcinomas, according to recent study.

Emerging Therapies Show Promise in Head and Neck Cancer

May 4th 2017

Aarti Bhatia, MD, highlights the newer single agents and combination treatments being investigated for patients with head and neck cancer.

Swallowing Exercises Crucial After RT in Head and Neck Cancer

May 4th 2017

Lynn Acton, MS, CCC (SLP), discusses the significance of swallowing modalities for patients with head and neck cancer.

Rationale for Targeting Galectin-1 in Head and Neck Cancer

May 4th 2017

Dhanya K. Nambiar, PhD, Stanford University, explains the rationale behind targeting Galectin-1 (Gal-1) in head and neck cancer.

Expert Sheds Light on Investigative Surgical Approaches in Head and Neck Cancer

May 3rd 2017

Benjamin L. Judson, MD, highlights the importance of a multidisciplinary team and shares insight on some of the advancements related to surgery for patients with head and neck cancer.

Dr. Burtness on Evolution of Molecular Testing in Head and Neck Cancer

May 3rd 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the evolution of molecular testing in head and neck cancer.

Dr. Seiwert on Final Thoughts on Immunotherapy in Head and Neck Cancer

May 1st 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses some final opinions on immunotherapy agents in the landscape of head and neck cancer.

PrimeMD, a Pain Reporting Smartphone Application for Patients Undergoing Head and Neck Radiation

May 1st 2017

A feasibility study of a smartphone application that patients undergoing radiation therapy for head and neck cancer can use to regularly report mucositis symptoms.

Dr. Papa on the Impact of CAR T Cell Trial in Head and Neck Cancer

April 27th 2017

Sophie Papa, PhD, MBBS, MRCP, medical oncologist, Clinical Academic Group, Department of Research Oncology, King’s College London, discusses the impact of a recent study of chimeric antigen receptor (CAR) T cells in head and neck squamous cell carcinoma.

Combinations with Radiation for Head and Neck Cancer

April 27th 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses combinations with radiation therapy for patients with head and neck cancer.

Expert Discusses Immunotherapy Advances in Head and Neck Cancer

April 25th 2017

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Dr. Seiwert on Managing Side Effects for Head and Neck Cancer Treatment

April 25th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Dr. Nambiar on Next Steps with Galectin-1 for Head and Neck Cancer

April 21st 2017

Dhanya K. Nambiar, PhD, Stanford University, discusses the next steps with targeting galectin-1 with radiation therapy and immune checkpoint inhibitors in patients with head and neck cancer.

Dr. Ciccolini on Dose Levels of Cetuximab in Head and Neck Cancer

April 21st 2017

Joseph Ciccolini, PhD, assistant professor in Pharmocokinetics, Aix-Marseille University, discusses dose levels of cetuximab (Erbitux) in patients with head and neck cancer.